In further pre-clinical studies, co-treatment of cells with paclitaxel and a JAK2 inhibitor, NVP-BSK805, could significantly reduce STAT3 phosphorylation, and in vivo tumor growth, when compared with paclitaxel alone (67). The gene discussed is JAK2; the disease is neoplasm.